Top

Investigational New Drugs

Published in:

01-11-1999

Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity

Authors: Len Neckers, Theodor W. Schulte, Edward Mimnaugh

Published in: Investigational New Drugs | Issue 4/1999

Title: Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity
Authors: Len Neckers
Theodor W. Schulte
Edward Mimnaugh
Publication date: 01-11-1999
Publisher: Kluwer Academic Publishers
Published in: Investigational New Drugs / Issue 4/1999
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1023/A:1006382320697

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 4/1999

Oral Topoisomerase 1 Inhibitors in Adult Patients: Present and Future

Matrix Metalloproteinase Inhibitors: Applications in Oncology

Orthotopic Metastatic Mouse Models for Anticancer Drug Discovery and Evaluation: a Bridge to the Clinic

Volume Contents

Activation-Induced Apoptosis of Peripheral Lymphocytes Treated with 7-Hydroxystaurosporine, UCN-01

Oncolytic Viruses

Keynote webinar | Spotlight on antibody–drug conjugates in cancer